Fulcrum to merge with Slate in all-stock deal after drug setback

Fulcrum Therapeutics said on Monday it would merge with privately held Slate Medicines in an all-stock deal, as ​the biotech looks to rebuild its pipeline after it ‌discontinued development of its lea...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。